keyword
MENU ▼
Read by QxMD icon Read
search

Radioiodine treatment

keyword
https://www.readbyqxmd.com/read/29656442/treatment-emergent-hypertension-and-efficacy-in-the-phase-3-study-of-e7080-lenvatinib-in-differentiated-cancer-of-the-thyroid-select
#1
Lori J Wirth, Makoto Tahara, Bruce Robinson, Sanjeev Francis, Marcia S Brose, Mouhammed Amir Habra, Kate Newbold, Naomi Kiyota, Corina E Dutcus, Elton Mathias, Matthew Guo, Steven I Sherman, Martin Schlumberger
BACKGROUND: Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT)...
April 14, 2018: Cancer
https://www.readbyqxmd.com/read/29650270/radioiodine-refractory-differentiated-thyroid-cancer
#2
REVIEW
Yuchen Jin, Douglas Van Nostrand, Lingxiao Cheng, Min Liu, Libo Chen
Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of these patients will become RAI-refractory (RR-DTC) with a poor prognosis. This review focuses on the most challenging and rapidly evolving aspects of RR-DTC, and we discuss the considerable improvement in more accurately defining RR-DTC, more effective therapeutic strategies, and describe the diagnosis, pathogenesis, and future prospects of RR-DTC...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29644472/pictorial-representation-of-illness-and-self-measure-revised-2-prism-r2-an-effective-tool-to-assess-perceived-burden-of-thyroid-cancer-in-mainland-china
#3
Yanbo Wang, Suyun Fan, Hongbiao Wang, Li Li, Yanyan Jia, Li Chai
PURPOSE: Thyroid cancer, especially differentiated thyroid cancer (DTC), is a highly prevalent chronic disease that is known to cause considerable distress, related both to the high recurrence and treatment of the disease. The Pictorial Representation of Illness and Self Measure-Revised 2 (PRISM-R2) has been developed as a visual measure to assess suffering. The aim of this study was to evaluate the ability of the instrument to identify patients with DTC with different levels of suffering who may need additional support care...
April 11, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29643668/the-radioprotective-effects-of-curcumin-and-trehalose-against-genetic-damage-caused-by-i-131
#4
Seyed Masoud Jafarpour, Mehdi Safaei, Mehran Mohseni, Morteza Salimian, Akbar Aliasgharzadeh, Bagher Fahood
Background: Thyroid cancer has been growing rapidly during the last decades. Radioiodine-131 (I-131) as an appropriate therapy modality is currently using in the treatment of cancer and hyperthyroidism diseases. This radiotracer is considered as a cause of oxidative DNA damage in nontarget cells and tissues. The aim of this study was to investigate the effects of curcumin and trehalose on the level of DNA double-strand breaks (DSBs) caused by I-131 in human lymphocytes. Materials and Methods: First, 6-mL blood samples were taken from each of the five volunteers...
April 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29628632/expression-of-bax-and-bcl2-genes-in-peripheral-blood-lymphocytes-of-patients-with-differentiated-thyroid-cancer
#5
Zari Hamivand, Gholamhassan Haddadi, Reza Fardid
Context: Thyroid cancer is the most common endocrine malignancy worldwide. Iodine-131 is used in the treatment of thyroid cancer with dosage of 100 mCi. In the medical applications of ionizing radiation besides the advantages such as diagnosis and treatment of diseases, the risks arising from exposure should be considered as well. Aims: The present study aimed to evaluate the changes in expression levels of apoptotic Bax and Bcl-2 and the ratio of Bax/Bcl-2, in the peripheral blood lymphocytes (PBLs) of patients with differentiated thyroid cancer (DTC)...
January 2018: Journal of Medical Physics
https://www.readbyqxmd.com/read/29623376/trifunctional-psma-targeting-constructs-for-prostate-cancer-with-unprecedented-localization-to-lncap-tumors
#6
James Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, Anastasia Nikolopoulou, Clarence Williams, David Schlyer, Yize Zhao, Dohyun Kim, John W Babich
PURPOSE: Treatment of late-stage prostate cancer by targeted radiotherapeutics such as131 I-MIP-1095 and177 Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand therapy (RLT) with177 Lu-PSMA-617 has not reached its full potential due to insufficient dose delivery to the tumor. We recently developed a dual-targeting radioiodinated ligand, RPS-027, that targets PSMA and uses albumin binding to enable good tumor uptake and significantly reduced kidney uptake in a preclinical model...
April 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29620212/larp7-in-papillary-thyroid-carcinoma-induces-nis-expression-through-suppression-of-the-shh-signaling-pathway
#7
Xiaomei Sui, Yana Sui, Yonghui Wang
The incidence of thyroid cancer has increased the past few decades, the most frequent type has been identified to be the papillary thyroid carcinoma (PTC). Following thyroidectomy, radioiodine ablation treatment on PTC is routinely performed. However, many patients do not benefit from radioiodine therapy. Therefore, novel targeted therapies to suppress tumor growth and improve radioiodine uptake are required. La ribonucleoprotein domain family member (LARP)7 is a member of the LARP family and functions as a potential suppressor of the progression of carcinoma...
April 5, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29613968/dosimetry-based-treatment-for-graves-disease
#8
Steve L Hyer, Brenda Pratt, Matthew Gray, Sarah Chittenden, Yong Du, Clive L Harmer, Glenn D Flux
OBJECTIVE: The aim of this retrospective study was to assess the long-term outcome of a personalized dosimetry approach in Graves' disease aiming to render patients euthyroid from a planned thyroid absorbed dose of 60 Gy. PATIENTS AND METHODS: A total of 284 patients with Graves' disease were followed prospectively following administration of radioiodine calculated to deliver an absorbed dose of 60 Gy. Patients with cardiac disease were excluded. Outcomes were analysed at yearly intervals for up to 10 years with a median follow-up of 37...
April 2, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29602820/dual-modality-immunopet-and-near-infrared-fluorescence-nirf-imaging-of-pancreatic-cancer-using-an-anti-prostate-cancer-stem-cell-antigen-psca-cys-diabody
#9
Kirstin A Zettlitz, Wen-Ting K Tsai, Scott M Knowles, Naoko Kobayashi, Timothy R Donahue, Robert E Reiter, Anna M Wu
Pancreatic cancer has a high mortality rate due to late diagnosis and the tendency to invade surrounding tissues and metastasize at an early stage. A molecular imaging agent that enables both pre-surgery antigen-specific positron emission tomography (immunoPET) and intra-operative near-infrared fluorescent (NIRF)-guidance could benefit diagnosis, staging and surgical resection of pancreatic cancer, which remains the only curative treatment. Methods: A dually labeled probe was developed based on A2 cys-diabody (A2cDb) targeting the cell surface antigen prostate stem cell antigen (PSCA) that is expressed in a majority of pancreatic cancers...
March 30, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29602223/cost-effectiveness-of-sialendoscopy-versus-medical-management-for-radioiodine-induced-sialadenitis
#10
David M Kowalczyk, J Randall Jordan, Scott P Stringer
OBJECTIVES/HYPOTHESIS: The medical management and radiographic identification of radioiodine-induced sialadenitis (RAIS) is challenging. This study utilizes a cost-effectiveness analysis to compare upfront sialendoscopy as both a diagnostic and therapeutic option versus multiple modalities of diagnostic radiography along with medical management. STUDY DESIGN: Literature review and cost-effectiveness analysis. METHODS: A literature review was performed to identify the outcomes of medical management, sialendoscopy, diagnostic radiography, and surgical complications...
March 30, 2018: Laryngoscope
https://www.readbyqxmd.com/read/29594058/trends-in-costs-of-thyroid-disease-treatment-in-denmark-during-1995-2015
#11
Line Tang Møllehave, Allan Linneberg, Tea Skaaby, Nils Knudsen, Lars Ehlers, Torben Jørgensen, Betina Heinsbæk Thuesen
Background: Iodine fortification (IF) may contribute to changes in costs of thyroid disease treatment through changes in disease patterns. From a health economic perspective, assessment of the development in costs of thyroid disease treatment in the population is pertinent. Objectives: To assess the trends in annual medicine and hospital costs of thyroid disease treatment during 1995-2015 in Denmark, i.e., before and after the introduction of mandatory IF in 2000...
March 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/29594056/2018-european-thyroid-association-eta-guidelines-for-the-management-of-amiodarone-associated-thyroid-dysfunction
#12
Luigi Bartalena, Fausto Bogazzi, Luca Chiovato, Alicja Hubalewska-Dydejczyk, Thera P Links, Mark Vanderpump
Treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction (amiodarone-induced hypothyroidism, AIH, and amiodarone-induced thyrotoxicosis, AIT). Both AIH and AIT may develop in apparently normal thyroid glands or in the presence of underlying thyroid abnormalities. AIH does not require amiodarone withdrawal, and is treated with levothyroxine replacement if overt, whereas subclinical forms may be followed without treatment. Two main types of AIT are recognized: type 1 AIT (AIT 1), a form of iodine-induced hyperthyroidism occurring in nodular goitres or latent Graves disease, and type 2 AIT (AIT 2), resulting from destructive thyroiditis in a normal thyroid gland...
March 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/29594055/occurrence-of-graves-orbitopathy-and-graves-hyperthyroidism-after-a-trauma-to-the-eye
#13
Elena Sabini, Ilaria Ionni, Roberto Rocchi, Paolo Vitti, Claudio Marcocci, Michele Marinò
Background: Graves' orbitopathy (GO) is believed to be the consequence of autoimmunity against antigens that are present both in the thyroid and orbital tissues. Massive release of thyroid antigens causes the appearance or deterioration of GO in patients with Graves' hyperthyroidism (GH), as it occurs following radioiodine treatment. In theory, a similar release of autoantigens may occur at the eye level, for example due to an orbital trauma or surgical manipulation. To our knowledge, this is the first report of a case of de novo appearance of GO and then GH after an eye trauma, possibly reflecting spreading of autoantigens and activation of the immune system against shared orbital and thyroid antigens...
January 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/29590674/-influence-of-glucocorticoid-therapy-on-intratherapeutic-biodistribution-of-131i-radioiodine-therapy-in-graves-disease
#14
Jörg Halstenberg, Wolfgang Tilman Kranert, Hüdayi Korkusuz, Amelie Mayer, Hanns Ackermann, Frank Grünwald, Christian Happel
AIM: Radioiodine therapy (RIT) is an important therapeutic method in the definitive treatment of Graves' disease (GD). However, RIT may trigger development of Graves' ophthalmopathy (GO) or exacerbate a pre-existing GO. Therefore, the procedure recommendation of the DGN (German Society of Nuclear Medicine) for RIT of benign thyroid diseases recommends an additional glucocorticoid therapy for patients with pre-existing GO. Aim of this study was to analyze the influence of a protective glucocorticoid therapy on131 I biokinetics during RIT of patients with GD...
April 2018: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29589552/evaluation-and-management-of-the-child-with-thyrotoxicosis
#15
Alexander K C Leung, Alexander A C Leung
BACKGROUND: Uncontrolled thyrotoxicosis, especially in early infancy, may cause irreversible damage to the central nervous system as well as profound effects on the function of many organs. Thyrotoxicosis has multiple etiologies and treatment depends on the underlying etiology. An accurate diagnosis is essential so that appropriate treatment can be initiated without undue delay. OBJECTIVE: To review in depth the evaluation, diagnosis, and treatment of children with thyrotoxicosis...
March 26, 2018: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
https://www.readbyqxmd.com/read/29567362/braf-v600e-mutation-in-papillary-thyroid-cancer-and-its-effect-on-postoperative-radioiodine-131-i-therapy-should-we-modify-our-therapeutic-strategy
#16
Maite Domínguez Ayala, Amaia Expósito Rodríguez, Amaia Bilbao González, Pablo Mínguez Gabiña, Teresa Gutiérrez Rodríguez, Emilia Rodeño Ortiz de Zarate, Maitane García Carrillo, Borja Barrios Treviño
INTRODUCTION: The BRAF V600E mutation in papillary thyroid cancer (PTC) has been associated with resistance to131 I. Our aim was to quantify the response to131 I after surgery in patients who had the mutation (BRAF+) and those who did not have the mutated gene (BRAF-). METHOD: A prospective cohort study was designed, from September 2015 to February 2016, which included patients with PTC receiving therapy after surgical treatment. Variables were described for age, gender, histology, tumor stage, thyroglobulin values before, 48h after and 6months after131 I; absorbed dose and % activity on days 2 and 7 and elimination time...
March 19, 2018: Cirugía Española
https://www.readbyqxmd.com/read/29562827/location-and-causation-of-residual-lymph-node-metastasis-after-surgical-treatment-of-regionally-advanced-differentiated-thyroid-cancer
#17
Jessa E Miller, Neal C Al-Attar, Owen H Brown, Gabrielle G Shaughness, Natalja P Rosculet, Anca Avram, David T Hughes
BACKGROUND: After initial surgical treatment of differentiated thyroid cancer (DTC) residual lymph node metastases are often found at the time of radioactive iodine (131-I) therapy. Recurrence of DTC is due to persistent disease not removed at initial surgery and that did not respond to 131-I treatment. This study aims to determine locations of, and reasons for, residual nodal metastases detected by 131-I scans with SPECT/CT obtained prior to radioiodine therapy following surgical treatment of DTC...
March 21, 2018: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29561759/epigenetic-modifications-in-thyroid-cancer-cells-restore-nis-and-radio-iodine-uptake-and-promote-cell-death
#18
Sabine Wächter, Alexander I Damanakis, Moritz Elxnat, Silvia Roth, Annette Wunderlich, Frederik A Verburg, Sebastian A Fellinger, Detlef K Bartsch, Pietro Di Fazio
Epigenetic modifications have been identified as being responsible for the de-differentiation of thyroid tissue and its malignant transformation. Cell proliferation inhibitory effects of the pan-deacetylase inhibitors panobinostat, SAHA and Trichostatin A (TSA), the modulation of the sodium iodide symporter (NIS; SLC5A5), thyroid transcription factor 1 (TTF1), high mobility group A2 (HMGA2), and H19 and their putative targeting miRNAs have been evaluated in vitro. The cell viability was measured in five thyroid cancer cell lines (FTC133, TPC1, BCPAP, 8505C, C643) by real time cell analyzer xCELLigence...
March 21, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29550843/-18-f-fdg-pet-ct-and-ultrasonogrpahy-in-differentiated-thyroid-carcinoma-patients-with-elevated-serum-levels-of-antithyroglobulin-antibody-negative-tg-and-whole-body-131-i-scan
#19
Jiao Liu, Baoping Liu, Yanxia Yu, Fangfang Chao, Yan Liu, Xingmin Han
OBJECTIVE: In the follow-up of patients with differentiated thyroid cancer (DTC), several patients had elevated serum levels of antithyroglobulin antibody (TgAb), undetectable serum thyroglobulin (Tg), and negative radioiodine whole body scan (131 I-WBS). We describe the use of neck ultrasonography (US) and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) imaging in these patients to investigate this clinically challenging problem and propose treating...
March 20, 2018: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29549769/hybrid-vision-fusion-system-for-whole-body-scintigraphy
#20
Marko Barjaktarović, Milica M Janković, Marija Jeremić, Milovan Matović
Radioiodine therapy in the treatment of differentiated thyroid carcinoma (DTC) is used in clinical practice for the ablation of thyroid residues and/or destruction of tumour tissue. Whole-body scintigraphy for visualization of the spatial 131I distribution performed by a gamma camera (GC) is a standard procedure in DTC patients after application of radioiodine therapy. A common problem is the precise topographic localization of regions where radioiodine is accumulated even in SPECT imaging. SPECT/CT can provide precise topographic localization of regions where radioiodine is accumulated, but it is often unavailable, especially in developing countries because of the high price of the equipment...
March 9, 2018: Computers in Biology and Medicine
keyword
keyword
20184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"